228 related articles for article (PubMed ID: 19469001)
1. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease.
Donadon V; Balbi M; Ghersetti M; Grazioli S; Perciaccante A; Della Valentina G; Gardenal R; Dal Mas M; Casarin P; Zanette G; Miranda C
World J Gastroenterol; 2009 May; 15(20):2506-11. PubMed ID: 19469001
[TBL] [Abstract][Full Text] [Related]
2. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
3. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
4. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.
Kawaguchi T; Taniguchi E; Morita Y; Shirachi M; Tateishi I; Nagata E; Sata M
Liver Int; 2010 Mar; 30(3):479-86. PubMed ID: 20040053
[TBL] [Abstract][Full Text] [Related]
5. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.
Donadon V; Balbi M; Valent F; Avogaro A
World J Gastroenterol; 2010 Jun; 16(24):3025-32. PubMed ID: 20572306
[TBL] [Abstract][Full Text] [Related]
6. The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey.
Kawaguchi T; Kohjima M; Ichikawa T; Seike M; Ide Y; Mizuta T; Honda K; Nakao K; Nakamuta M; Sata M
J Gastroenterol; 2015 Mar; 50(3):333-41. PubMed ID: 24912965
[TBL] [Abstract][Full Text] [Related]
7. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus.
Donadon V; Balbi M; Zanette G
Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):465-7. PubMed ID: 19817667
[No Abstract] [Full Text] [Related]
8. [Study on the risk of hepatitis B-related cirrhosis combined with type 2 diabetes mellitus for the occurrence of primary hepatocellular carcinoma].
Zhang LL; Li YF; Zhang C; Wu XF; Ma Y; Li L
Zhonghua Gan Zang Bing Za Zhi; 2019 Oct; 27(10):788-792. PubMed ID: 31734994
[No Abstract] [Full Text] [Related]
9. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
11. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
12. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Wang P; Kang D; Cao W; Wang Y; Liu Z
Diabetes Metab Res Rev; 2012 Feb; 28(2):109-22. PubMed ID: 21898753
[TBL] [Abstract][Full Text] [Related]
14. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
16. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.
Bosetti C; Franchi M; Nicotra F; Asciutto R; Merlino L; La Vecchia C; Corrao G
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):771-8. PubMed ID: 26013675
[TBL] [Abstract][Full Text] [Related]
17. Metformin does not improve survival in patients with hepatocellular carcinoma.
Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes--National cohort of Taiwan Diabetes Study.
Li CI; Chen HJ; Lai HC; Liu CS; Lin WY; Li TC; Lin CC
Int J Cancer; 2015 Jun; 136(11):2668-79. PubMed ID: 25387451
[TBL] [Abstract][Full Text] [Related]
19. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
20. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
